Establishment of a Murine Model of Breast Cancer Expressing Human Epidermal Growth Factor Receptor 2 (4T1‑Her2) Publisher Pubmed



Vk Bakhtiarvand Vahid KHAKI ; K Ramezaniali Akbari KHADIJEH ; F Sadri FATEMEH ; Fn Haghighat Farzaneh NOTASH ; M Hojjatfarsangi MOHAMMAD ; F Shokri FAZEL ; M Jedditehrani MAHMOOD ; M Shabani MAHDI
Source: Journal of Cancer Research and Therapeutics Published:2024

Abstract

Aim: Although people with HER2‑positive breast cancer benefit from approved HER2‑targeted therapy, acquiring resistance to the therapies occurs. Animal models can play a part in gaining a deep understanding of such a process and addressing questions concerning developing and improving immunotherapy approaches. Materials and Methods: To develop such a model, we transfected murine 4T1 cells with the pCMV6‑Neo‑HER2 construct and evaluated HER2 expression and its effects on the established cell line behavior in vitro and in vivo. Results: Data illustrated that human HER2 protein was expressed on isolated 4T1‑HER2 clones in vitro and in vivo. Except for proliferation over 48 hours, such expression did not change 4T1‑HER2 characteristics compared to 4T1 in vitro. Notwithstanding the reduction in proliferation, the rate of tumorigenicity was 90% in challenged mice and Herceptin therapy significantly decreased tumors’ growth and metastasis compared to the control group. Conclusion: We describe a murine model for HER2‑positive breast cancer not only helping shed light on the mechanisms by which the tumor evades antitumor immunity but also playing a key role in making breast cancer more sensitive to novel immunotherapy modalities. © 2024 Elsevier B.V., All rights reserved.